Pfizer Inc (PFE) and BioNTech Announces Positive Topline Results for Phase 3 of COMIRNATY COVID-19 Vaccine

Pfizer Inc. (NYSE:PFE) is one of the Blue Chip Stocks to Buy with the Lowest PE Ratios. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech announced positive topline results from their Phase 3 trial of the LP.8.1-adapted monovalent COMIRNATY COVID-19 vaccine for the 2025-2026 season.

The study evaluated adults aged 65 and older, along with adults aged 18 to 64, having at least one risk condition for severe COVID-19. The vaccine showed a strong immune response by increasing neutralizing antibodies targeting the LP.8.1 sublineage of SARS-CoV-2 by at least four times within 14 days of vaccination. Notably, the safety profile of the vaccine was consistent with prior studies, and no new safety concerns were identified. These positive findings reinforce pre-clinical data and support the recent FDA approval of the vaccine for the targeted groups.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, and manufacturing healthcare products.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.